| Active Not Recruiting | A Study of Botensilimab in Participants With Metastatic Pancreatic Cancer Metastatic Pancreatic Ductal Adenocarcinoma | Phase 2 | 2023-03-27 |
| Active Not Recruiting | A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma Advanced Melanoma | Phase 2 | 2022-12-12 |
| Active Not Recruiting | A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer Metastatic Colorectal Cancer | Phase 2 | 2022-11-30 |
| Completed | Study of AGEN1571 in Participants With Advanced Solid Tumors Advanced Solid Tumor | Phase 1 | 2022-07-19 |
| Completed | A Study Investigating AGEN1777 in Participants With Advanced Solid Tumors Advanced Cancer | Phase 1 | 2021-10-04 |
| Withdrawn | A Phase II Study of Balstilimab Independently or in Combination With Zalifrelimab in Advanced Cervical Cancer Cervical Cancer | Phase 2 | 2021-10-01 |
| Withdrawn | Balstilimab Versus Investigator Choice Chemotherapy in Patients With Recurrent Cervical Cancer (BRAVA) Advanced Cancer, Metastatic Cervical Cancer | Phase 3 | 2021-08-02 |
| Withdrawn | AGEN2034 & AGEN1884 in Patients With Recurrent, Inoperable Angiosarcoma Angiosarcoma | Phase 2 | 2021-02-01 |
| Terminated | A Study in Subjects With Advanced Solid Tumors Advanced Solid Tumor | Phase 1 | 2019-12-10 |
| Completed | Anti-CD137 and Anti-CTLA-4 Monoclonal Antibody in Patients With Advanced Cancer Advanced Cancer | Phase 1 | 2019-09-26 |
| Terminated | RaPiDS- A Phase 2 Study of Anti-PD-1 Independently or in Combination With Anti-CTLA-4 in Second-Line Cervical Cervical Cancer | Phase 2 | 2019-06-01 |
| Completed | Phase 1a Study to Evaluate Immunogenicity of ASV® Solid Tumor, Adult | Phase 1 | 2019-05-16 |
| Active Not Recruiting | Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer Advanced Cancer, Angiosarcoma, Colorectal Cancer Without Liver Metastases | Phase 1 | 2019-03-20 |
| Completed | Subjects With Metastatic or Locally Advanced Solid Tumors, and Expansion Into Select Solid Tumors (Cervical) Cervical Cancer | Phase 1 / Phase 2 | 2017-12-18 |
| Terminated | Study of AGEN1884 With Pembrolizumab in 1L NSCLC NSCLC Stage IV | Phase 2 | 2017-10-04 |
| Completed | A Study of AGEN2034 in Advanced Tumors and Cervical Cancer Advanced Cancer, Cervical Cancer | Phase 1 / Phase 2 | 2017-04-11 |
| Terminated | Safety and Tolerability Study of AutoSynVax™ Vaccine in Subjects With Advanced Cancer Advanced Cancer | Phase 1 | 2017-01-01 |
| Completed | AGEN1884, an Anti-CTLA-4 Human Monoclonal Antibody in Participants With Advanced or Refractory Cancer and Who Advanced Solid Cancers, Advanced Solid Cancers Refractory to PD-1 and PD-L1 Therapies | Phase 1 / Phase 2 | 2016-04-01 |
| Completed | Biological Efficacy Study of HerpV Vaccine With QS-21 to Treat Participants With Recurrent Genital Herpes Herpes Simplex Type 2 | Phase 2 | 2012-10-29 |
| Terminated | Study of Vitespen (HSPPC-96, Oncophage ®) for Immune Response Assessment in Participants With Resectable Renal Renal Cell Carcinoma | Phase 2 | 2010-01-01 |
| Completed | Study of L-NDDP (Aroplatin) in Patients With Advanced Solid Malignancies or B-Cell Lymphoma Malignancies, B-Cell Lymphoma | Phase 1 | 2006-03-01 |
| Completed | Trial Evaluating Safety, Tolerability and Immune Response of AG-707 Genital Herpes | Phase 1 | 2006-03-01 |
| Terminated | Clinical Trial Studying a Personalized Cancer Vaccine in Patients With Non-metastatic Kidney Cancer Kidney Cancer, Renal Cell Carcinoma | Phase 3 | 2005-05-01 |
| Completed | Study of the Feasibility to Derive Vaccine From Tumor Tissue in Patients With Non-Small Cell Lung Cancer Non-Small-Cell Lung Carcinoma, Lung Cancer, Pulmonary Cancer | Phase 2 | 2003-09-01 |
| Terminated | AG-858 in Patients Who Are Cytogenetically Positive After Treatment With Gleevec™ Leukemia, Myeloid, Chronic | Phase 2 | 2003-03-01 |
| Terminated | Trial to Compare the Routes of Administration of an Investigational, Personalized, Therapeutic Cancer Vaccine Renal Cell Carcinoma | Phase 2 | 2002-07-01 |
| Completed | Study of Heat Shock Protein-Peptide Complex (HSPPC-96) Versus IL-2/DTIC for Stage IV Melanoma Malignant Melanoma | Phase 3 | 2002-03-01 |
| Completed | Survival Study Of Oncophage® vs. Observation In Patients With Kidney Cancer Renal Cell Carcinoma | Phase 3 | 2000-06-01 |
| Completed | A Safety and Effectiveness Study of Vaccine Therapy in Patients With Indolent Lymphoma Lymphoma, Follicular, Lymphoma, Small Lymphocytic | Phase 2 | 2000-03-01 |
| Available | Expanded Access Program (EAP) Designed to Provide Access to Botensilimab and Balstilimab Before Regulatory App Colorectal Cancer (CRC), Pancreatic Cancer, Non-Small Cell Lung Cancer (NSCLC) | — | — |
| Available | Expanded Access for Cancer Treatment With Balstilimab (AGEN2034) and Zalifrelimab (AGEN1884) Cancer | — | — |